pour la recherche uniquement
Réf. Catalogue: S2310
Structure chimique
| Cibles apparentées | PI3K Akt mTOR GSK-3 ATM/ATR DNA-PK AMPK PDPK1 PTEN PP2A |
|---|---|
| Autre Antineoplastic and Immunosuppressive Antibiotics Inhibiteurs | Staurosporine (STS) Cyclosporin A Oligomycin A (MCH 32) Puromycin Dihydrochloride Nigericin sodium salt Geldanamycin (NSC 122750) Streptozotocin (STZ) Sodium Monensin (NSC 343257) Hygromycin B Cephalomannine |
| Lignées cellulaires | Type d'essai | Concentration | Temps d'incubation | Formulation | Description de l'activité | PMID |
|---|---|---|---|---|---|---|
| human UACC-903 cells | Cytotoxicity assay | Cytotoxicity against human UACC-903 cells after 72 hrs by MTS assay, IC50=5.1 μM | ||||
| Vero E6 cells | Function assay | Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA, EC50=6.5 μM | ||||
| human UACC-903 cells | Cytotoxicity assay | Cytotoxicity against human UACC-903 cells after 24 hrs by MTS assay, IC50=7.45 μM | ||||
| human A549 cells | Cytotoxicity assay | Cytotoxicity against human A549 cells after 72 hrs by MTS assay, IC50=7.75 μM | ||||
| human CEM cells | Cytotoxicity assay | Cytotoxicity against human CEM cells, IC50=10.9 μM | ||||
| HEK293 cells | Function assay | Agonist activity at RXRalpha in HEK293 cells assessed as transcriptional activation after 48 hrs by luciferase reporter gene assay, EC50=11.8 μM | ||||
| human A549 cell | Cytotoxicity assay | 24 h | Cytotoxicity against human A549 cells after 24 hrs by MTS assay, IC50=12.51 μM | |||
| human HT-29 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay, IC50=13.24 μM | |||
| human PBM cells | Cytotoxicity assay | Cytotoxicity against human PBM cells, IC50=16.1 μM | ||||
| Hep-G2 cells | Cytotoxicity assay | Cytotoxicity of compound against human liver tumor cell line (Hep-G2) was determined, IC50=16.5 μM | ||||
| human HepG2 cells | Proliferation assay | 24 h | Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay, IC50=16.5 μM | |||
| human K562 cells | Proliferation assay | Antiproliferative activity against human K562 cells by MTT assay, IC50=21.1 μM | ||||
| Vero cells | Cytotoxicity assay | Cytotoxicity against Vero cells, IC50=22.5 μM | ||||
| human A2780 cells | Proliferation assay | Antiproliferative activity against cisplatin-sensitive human A2780 cells by MTT assay, IC50=30.5 μM | ||||
| human SPC-A1 cells | Proliferation assay | Antiproliferative activity against human SPC-A1 cells by MTT assay, IC50=36.1 μM | ||||
| HUVEC cells | Function assay | 20 μM | 24 h | Antimigratory activity against human HUVEC cells at 20 uM after 24 hrs by wound-healing assay | ||
| HEK293 cells | Function assay | 24-48 h | Agonist activity at human RXR-alpha expressed in HEK293 cells coexpressing with pCMX-beta-gal after 24 to 48 hrs by luciferase reporter gene assay | |||
| human SH-SY5Y cells | Function assay | 10 μM | 30 mins | Neuroprotective activity in human SH-SY5Y cells assessed as inhibition of CHP and TBHP-induced cell death at 10 uM incubated for 30 mins prior to challenge measured after 3 hrs by MTT assay | ||
| Cliquez pour voir plus de données expérimentales sur la lignée cellulaire | ||||||
| Poids moléculaire | 266.334 | Formule | C18H18O2 |
Stockage (À compter de la date de réception) | |
|---|---|---|---|---|---|
| N° CAS | 35354-74-6 | Télécharger le SDF | Stockage des solutions mères |
|
|
| Synonymes | NSC 293100 | Smiles | C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C | ||
|
In vitro |
DMSO
: 53 mg/mL
(198.99 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Étape 1 : Saisir les informations ci-dessous (Recommandé : Un animal supplémentaire pour tenir compte des pertes pendant l'expérience)
Étape 2 : Saisir la formulation in vivo (Ceci est seulement le calculateur, pas la formulation. Veuillez nous contacter d'abord s'il n'y a pas de formulation in vivo dans la section Solubilité.)
Résultats du calcul :
Concentration de travail : mg/ml;
Méthode de préparation du liquide maître DMSO : mg médicament prédissous dans μL DMSO ( Concentration du liquide maître mg/mL, Veuillez nous contacter d'abord si la concentration dépasse la solubilité du DMSO du lot de médicament. )
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouterμL PEG300, mélanger et clarifier, puis ajouterμL Tween 80, mélanger et clarifier, puis ajouter μL ddH2O, mélanger et clarifier.
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouter μL Huile de maïs, mélanger et clarifier.
Note : 1. Veuillez vous assurer que le liquide est clair avant d'ajouter le solvant suivant.
2. Assurez-vous d'ajouter le(s) solvant(s) dans l'ordre. Vous devez vous assurer que la solution obtenue, lors de l'ajout précédent, est une solution claire avant de procéder à l'ajout du solvant suivant. Des méthodes physiques telles que le vortex, les ultrasons ou le bain-marie chaud peuvent être utilisées pour faciliter la dissolution.
| Targets/IC50/Ki |
Akt-phosphorylation
MEK
|
|---|---|
| In vitro |
Honokiol shows pro-apoptotic effects in melanoma, sarcoma, myeloma, leukemia, bladder, lung, prostate, oral squamous cell carcinoma and colon cancer cell lines. This compound is effective on inducing apoptosis in SVR angiosarcoma cells. Treatment of SVR cells with this chemical causes decreased phosphorylation of MAP kinase, akt, and c-src. In addition, it potentiates TRAIL-mediated apoptosis, and its cytotoxicity is partially abrogated by neutralizing antibodies to TRAIL. This compound also has direct antiangiogenic activity, in that it blocks the phosphorylation and rac activation due to VEGF-VEGFR2 interactions. It causes apoptosis in CLL cells through activation of caspase 8, followed by caspase 9 and 3 activation. This chemical prevents interleukin-4-mediated survival of CLL cells, and potentiats the cytotoxicity of CB-1348, FaraA, and 2-CdA. It kills myeloma cells from relapsed patients at doses that does not kill PBMCs. Caspase 3, 7, 8, and 9 are induced by this compound treatment, as well as PARP cleavage. It is found to induce apoptosis in the colon cancer cell lines RKO. This chemical potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. It may act as a potent anti-inflammatory agent with multipotential activities due to an inhibitory effect on the PI3K/Akt pathway. |
| In vivo |
Honokiol is highly effective against SVR angiosarcoma in nude mice. This compound inhibits the growth of RKO cells in murine xenografts. It prevents the growth of MDA-MD-231 breast cancer cells in murine xenografts. |
Références |
|
| Méthodes | Biomarqueurs | Images | PMID |
|---|---|---|---|
| Western blot | p-EGFR / p-AKT / p-STAT3 / p-ERK / p-GSK3α/β / Bax / p-pRb / p-BAD / IκBα / CDK2 / CDK4 / Cyclin D1 p-Lyn / Lyn / p-PI3K |
|
27458163 |
| Immunofluorescence | Vimentin / Occludin IκBα / NF-κB p65 |
|
24508063 |